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Abstract Diarrhea is considered as an important cause of
morbidity and mortality, even though one of the main rea-
sons of death following diarrhea is initiated by dysentery. In
recent years, the consumption of probiotics has been pro-
posed for the treatment of infectious diarrhea. Despite most
of the studies on probiotics have focused on acute watery
diarrhea, few studies in the field of dysentery have found
beneficial effects of probiotics. This study is a randomized
double-blind clinical trial. The patients were randomly
placed into control and case groups. In the intervention
group, the patients received probiotics in the form of
Kidilact® sachet, which contained high amounts of 7-strain
friendly bacteria strains of Lactobacillus casei, Lactobacillus
acidophilus, Lactobacillus rhamnosus, Lactobacillus
bulgaricus, Bifidobacterium infantis, Bifidobacterium breve,
and Streptococcus thermophiles. On the other hand, the pa-
tients in the control group received placebo sachets on a
daily basis for 5 days. It is notable that the treatment proto-
col of acute dysentery was done on both groups. The results
of this study showed significant differences in the duration
of blood in diarrhea between probiotic consumers (2.62 days)
and the control group (3.16 days) (P value = 0.05).
Additionally, significant differences in the average length
of hospitalization in probiotic consumers (3.16 days) and
control (3.66 days), (P value = 0.02) could be claimed that
the consumption of probiotics is effective in reducing the
duration of dysentery and diarrhea. The results of this study
suggest that the use of probiotics can be effective in reduc-
ing the duration of blood in diarrhea. This study was also
recorded in the Iran center of clinical trials registration da-
tabase (IRCT2014060617985N1).
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Introduction
Diarrheal diseases are among the major causes of child mor-
tality in developing countries [1]. The World Health
Organization (WHO) has defined diarrhea as an unusual
movement of bowel that liquid stools occur at least three times
a day [2]. However, change in the bowel consistency com-
pared to its previous form has been considered to be a more
important factor than the number of bowel movements, espe-
cially in the first months of life [3]. Diarrhea falls within three
categories, namely acute watery diarrhea, chronic diarrhea,
and bloody diarrhea (also named dysentery). From among
these types of diarrhea, dysentery is responsible for 20% of
the deaths resulting from diarrhea [4, 5]. The essential factors
recommended by the World Health Organization for the con-
trol of acute gastroenteritis include the use of oral rehydration
solution (ORS) with reduced osmolality and, if needed, intra-
venous fluids and zinc supplements. These have been proved
to reduce the severity of diarrhea during treatment. ORS con-
sumption declines the mortality and disability caused by diar-
rhea but does not influence the treatment length and severity
of the disease [6–8]. Many studies have suggested the con-
sumption of probiotics as an adjunct method for the treatment
of acute diarrhea. The term probiotic is originally a Greek
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word meaning Bfor life.^ This term was first used by Lilly and
Stillwell in 1965 to describe the reinforcing effect of a micro-
organism on the growth of other microorganisms. From that
time on, multiple definitions were proposed until in 1985
when Fuller gave a new definition for probiotics as Ba live
microbial feed supplement which beneficially affects the host
animal by improving its intestinal microbial balance.^ The
World Health Organization has referred to probiotics as the
live microorganisms that will have benefits to the host’s health
when consumed in adequate amounts [9, 10]. Probiotics are
now used in various fields of prevention and treatment, espe-
cially in acute infectious diarrhea [11]. The results of a sys-
tematic review of 56 studies on infants and children showed
that the consumption of probiotics is safe and significantly
effective in reducing the duration and the frequency of acute
infectious diarrhea [12]. To date, a variety of probiotics, in-
cluding lactobacilli, which are the bacteria and saccharomyces
of a fungus have been identified and their effects on different
diseases, such as acute gastroenteritis, have been investigated.
The use of yogurt, as a probiotic, has been recognized effec-
tive in the treatment of diarrhea since ancient times, and, to-
day, its beneficial effects in the treatment of diarrhea have
been reported in many studies [13]. In the case of bloody
diarrhea and dysentery, the main treatment includes the use
of antibiotics and rehydration where the prescribed antibiotics
are considered based on the desired pathogens [14]. In recent
years, the use of probiotics has been proposed to reduce the
duration and severity of infectious diarrhea treatment in the
clinical field. Although most of the studies on probiotics have
put their main focus on acute watery diarrhea, the effective-
ness of Lactobacillus and Saccharomyces in the treatment of
acute diarrhea and dysentery has been supported by the few
studies conducted on dysentery [15, 16]. However, some
others assert that there are not enough research findings yet
to recommend the clinical use of probiotics in the treatment of
diarrhea routinely [17]. The mechanism and effectiveness of
probiotics usually depend on the interaction of probiotic mi-
croorganisms with one’s specific normal flora and immune
cells of the intestinal mucosa. From among the effects of
probiotics, one can refer to such items as the stimulation of
the immune system, reduced competition for the use of nutri-
ents available in the intestine, connection to the intestinal
membrane wall and mucus, and prevention of the connection
of harmful factors, as well as the production of antimicrobial
substances (H2S, bacitracin, and fatty acids). In addition,
probiotics lead to the elimination of harmful microorganisms
in the digestive system due to the deconjugation of bile salts
and pH reduction [17–19]. From the intestinal flora,
Bifidobacteria and Lactobacillus have an important role in
health. The prescription of probiotics leads to some changes
in microbial profile and metabolic activities of stool in both
infants and adults. Although these changes are slight, they are
sufficient to modify the disease process in most of the times if
prescribed in pathological conditions. In most cases, the pre-
scription of probiotics leads to an increase in the number of
Bifidobacteria and Lactobacillus, to the decrease of stool PH,
and to the decline in bacterial enzyme activity [20]. The effect
of probiotics on diarrhea and other gastrointestinal disorders
can come into play very quickly because the substances se-
creted by probiotics quickly affect the intestinal wall.
However, it takes more time for the reinforcing effects of the
immune system on other diseases to come into play [21].
Although the majority of the studies in the field of probiotics’
prescription have been done on pediatric acute diarrheal dis-
eases, probiotics are used in the treatment of adult and pedi-
atric diarrhea, diarrhea caused by antibiotics, allergies, and
colitis. Although many studies refer to the effect of probiotics
in the prevention of diarrhea, the American Academy of
Pediatrics does not recommend it except in special circum-
stances, such as child care centers [21–23]. The present study
was conducted to evaluate the effect of available probiotics
(Kidilact®), on the length and severity of dysentery in infec-
tious control and children’s wards. Similar to other countries
and other regions of Iran, dysentery in Kashan occupies a
large number of hospital beds each year and is the main con-
cern of a large number of outpatient visitors to pediatric and
infectious clinics. It is noteworthy that no similar studies have
been undertaken in this region and that few studies in this
domain have been done in other countries, which have result-
ed in controversial findings [24, 25]. Hence, this study is car-
ried out to investigate the effectiveness of probiotics in the
improvement of dysentery. In case of the proof of their effec-
tiveness, it is hoped that the use of probiotics can reduce the
severity and complication of this disease as well as the eco-
nomic burden imposed by this disease to some extent. In fact,
the control of this disease will be more feasible in the case of
reduced duration of the treatment.
Materials and Methods
This study is a randomized double-blind clinical trial. The pa-
tients referring to Shahid Beheshti Hospital of Kashan in 2014
were admitted in the infectious control and children’s wards
(above 12 years) because of fever and bloody diarrhea. The
criteria for inclusion in this study were hospitalization in the
infectious control and children’s wards with complaints of fever
and dysentery, and active stool test. However, the exclusion
criteria were severe malnutrition, immunodeficiency, and the
consumption of antidiarrheal drugs or antibiotics. Regarding
the results of previous studies [26], a sample size of 50 patients
was considered (totally 100 patients) suitable for each group.
Dysentery diagnosis was proved by the stool test containing
RBC or WBC, and the patients with severe malnutrition, immu-
nodeficiency or users of antidiarrheal drugs or antibiotics were
excluded from the study. For data collection, the patients were
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randomly assigned to case and control groups after obtaining the
authorization of hospital officials and explaining the research
objectives to the hospital as well as receiving prior written con-
sent from the patients. In the intervention group, the patients
consumed the probiotics produced by Zisttakhmir Company in
the form of Kidilact® sachet. This is a particular probiotic-
probiotic combination (synbiotics) for children over 2 years that
contains high amounts of 7-strain friendly bacteria strains, such
as a child-specific strain BBifidobacterium infantis^ along with
prebiotic fructo-oligosaccharide (contributing to the growth and
activity of probiotics). Its formula has been prepared specifically
for children so that they can consume it easily. The strains used in
the production of probiotics include Lactobacillus casei,
Lactobacillus acidophilus, Lactobacillus rhamnosus,
Lactobacillus bulgaricus, B. infantis, Bifidobacterium breve,
and Streptococcus thermophiles. In the control group, the pa-
tients received two placebo sachets every day and were pre-
scribed for 5 days. In addition, the treatment protocol of acute
dysentery was done on both groups where 50 mg/kg ceftriaxone
was taken each day in the children’s ward and 1 g of it was taken
every 12 h in the infectious control ward for 3 to 5 days. The
essential data including demographic data (age, gender), stool
smear results, body temperature, type of antibiotics, dysentery,
and fever were collected through looking into the patients’med-
ical records and interrogative of the patients or their companions
[27–29]. The improvement criteria were including the number of
diarrhea less than three times a day, removal of blood in the stool,
and the fever recovery.
Randomization and Blinding
To this end, both groups, in addition to receiving the routine
treatment of dysentery, received the probiotic and placebo
drug in the form of medicinal sachet, designing in the same
size and color. It should be mentioned that a numerical code
from 1 to 100 had been recorded on each sachet and numbers
of each group were determined by block randomization.
Ethical Consideration
All procedures performed in studies involving human partic-
ipants were in accordance with the ethical standards of the
institutional and national research committee and with the
1964 Helsinki declaration and its later amendments. This trial
was registered at www.irct.ir as IRCT2014060617985N1.
Statistical Method
The Kolmogorov-Smirnov test was applied to determine the
normal distribution of variables. The analyses were carried out
based on the intention-to-treat principle. To detect differences
in anthropometric measures and the dietary intakes between
the two groups, we applied one-way, but two-tailed indepen-
dent sample Student’s t tests. These analyses were done using
analysis of variance (ANOVA) [30–34]. P values <0.05 were
considered statistically significant. All statistical analyses
were done using the Statistical Package for Social Science
version 19 (SPSS Inc., Chicago, IL, USA).
Results
The mean value of age was 42.12 years for the probiotic-
treated group, which consisted of 27 male and 23 female par-
ticipants. On the other hand, the mean value of age for the
control group was equal to 39.56 years and this group
consisted of 25 male and 25 female participants. In addition,
both groups were in similar situations in terms of temperature
at the time of hospitalization in such a way that the average
temperature at that time was 38.92 and 38.75 °C in the
probiotic-treated group and in the control group, respectively
(Table 1). There was not a statistically significant difference
between the groups in terms of the duration of fever (P 0.05)
and, thereby, probiotics did not stop fever (Table 2).
The presented data indicated a significant difference in the
duration of blood in diarrhea between probiotic consumers
(2.62) and the control group (3.16) at the significance level
of 0.01 (P < 0.05), and it can be claimed that the consumption
of probiotics is effective in reducing the duration of diarrhea
blood (Table 3). The clinical trial results presented significant
improvement of diarrhea in probiotic consumers compared to
the control group (P value = 0.03) (Tables 4 and 5).
Furthermore, consumption of probiotics significantly showed
direct relationship with reducing the duration of hospitaliza-
tion (P = 0.02).
Discussion
The patients had average age of 42.12 years for the probiotic-
treated group consisting of 27 male and 23 female partici-
pants. On the other hand, the mean value of age for the control
group was equal to 39.56 years and this group consisted of 25
Table 1 Comparison of temperature between the groups at the time of
hospitalization
Group Mean (°C) SD P value*
Probiotics 38.92 0.81 0.28
Control 38.75 0.78
*Statistical significance was attained when P value <0.05
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male and 25 female participants. There was no statistically
significant difference between the two groups in terms of
age and gender, and, thereby, the potential confounding effect
of these two factors was deleted. Additionally, both groups
were in similar situations in terms of fever at the time of
hospitalization such that the average temperature at that time
was 38.92 and 38.75 °C in the probiotic-treated group and in
the control group, respectively. Duration of diarrhea prior to
admission was 2.48 and 2.64 in the probiotic-treated group
and in the control group, respectively. There was no signifi-
cant difference between the groups in terms of the duration of
fever, and, thereby, probiotics did not stop fever. Considering
the presence of the significant difference in the duration of
blood in diarrhea between probiotic consumers (2.62 days)
and the control group (3.16 days) at the significance level of
0.01 (P < 0.05), and the consumption of probiotics can be
considered effective in reducing the duration of dysentery. In
a study, the effect of probiotic Bifidobacterium was examined
on the treatment of patients with acute dysentery. In this re-
search, patients in the intervention group received probiotics
in addition to standard treatment during the first 2 days of
disease resulting in the reduction of toxicity, pain, and dysen-
tery in comparison with the control group [35]. This issue is
directly related to reducing the duration of diarrhea in the
present study.
In another study, 245 children with intestinal infection were
studied and the effect of Bifidobacterium, probiotics, was in-
vestigated on Escherichia coli. In this study, hemolytic E. coli
was isolated from 47.3%, enteropathogenic E. coli from
12.2%, Shigella from 18.3%, and Salmonella from 1.8% of
the patients. Bifidobacterium had a good therapeutic effect on
enteropathogenic E.coli, including hemolytic forms [36].
Moreover, Vandenplas and colleagues by using of probiotics
significantly reduced the duration of diarrhea in acute infec-
tious gastroenteritis [37]. In the current study, the consump-
tion of probiotics was also effective in shortening the duration
of dysentery.
During a study on children with acute diarrhea, the inter-
vention group received probiotic plus ORS and control group
only ORS, but the use of probiotic (Lactobacillus) had no
significant effect in reducing the frequency and duration of
diarrhea and vomiting as well as shortening duration of hos-
pitalization [25]. Even so, the consumption of probiotic in the
current study reduced the duration of hospitalization due to
dysentery.
In another research, 75 children aged 5–50 months with
rotavirus gastroenteritis were tested in three equal groups. In
the first group, the patients were treated with fungal probiotic
(Saccharomyces boulardii), the second group was adminis-
tered with bacterial probiotic (Bifidobacterium lactis), and
the third group received regimen with no probiotic. The dura-
tion of diarrhea was 6.6 days in the first group, 4.1 days in the
second group, and 7 days in the third group. The use of
probiotics has been significantly effective in decreasing diar-
rhea duration. The effect of B. lactis as a bacterial probiotic
was higher than the fungal probiotic [38].
In a study of Francavilla to evaluate the effect of
Lactobacillus reuteri versus placebo in children aged 6–
36 months with acute diarrhea, 35 children received probiotic
(L. reuteri) and 34 patients placebo.The diarrhea duration was
2.1 days in the probiotic group while in the control group was
3.3 days. In probiotic group, on the second and third days of
treatment, 55 and 45% of patients had still diarrhea, respec-
tively, while this statistic was respectively 82 and 74% in the
control group; these differences were statistically significant.
But duration of hospitalization was not significantly different
[26]. Conversely, in the present study, duration of hospitaliza-
tion was significantly different between the two groups.
According to updated guidelines on the treatment of chil-
dren with acute gastroenteritis in Europe, administration of
certain probiotics such as Lactobacillus or S. boulardii can
reduce the duration and severity of diarrhea [39]. The results
of an in vitro investigation of L. casei on antibiotic-resistant
Shigella showed that the probiotic strongly inhibited the
growth of Shigella [40].
Table 3 Comparison of




Group Mean SD P value*
Probiotics 2.62 1.17 0.01
Control 3.16 1.05
*Statistical significance was attained when
P value <0.05
Table 2 Comparison of
temperature between the
groups in the duration of
hospitalization
Group Mean SD P value
Probiotics 2.54 1.23 0.11
Control 2.92 1.15
Table 4 Comparison of




Group Mean SD P value
Probiotics 3.04 1.16 0.03
Control 3.52 1.01




Group Mean SD P value
Probiotics 3.16 1.18 0.02
Control 3.66 0.91
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Due to the significant differences (P = 0.0) observed in the
diarrhea duration in probiotic consumers (3.04) compared to
the control group (3.52), probiotic taking can be effective in
reducing the duration of diarrhea. In addition, considering the
significant differences (P = 0.02) found in the duration of
hospitalization in probiotic consumers (3.16) compared to
the control group (3.66), and probiotic taking can be effective
in reducing the duration of hospitalization.
Conclusion
Although the significant difference observed in the duration of
dysentery between the probiotic consumers (2.62 days) and
the control group (3.16 days) at the significance level of
0.01 (P < 0.05), however, more research clinical trial studies
with large sample sizes in other regions are recommended,
and if the results of the present research was confirmed,
probiotics could be proposed for including in the treatment
protocol of dysentery.
Acknowledgements The researcher wishes to express his appreciation
to the full cooperation of the patients who participated in this study and
the Clinical Research Center of Shahid Beheshti Hospital. The financial
support for this research was provided by a grant no. 93137 from the
Research Deputy of Kashan University of Medical Sciences.
Compliance with Ethical Standards
Ethical Responsibilities of Authors This paper is our original unpub-
lishedwork and it has not been submitted to any other journal for reviews.
Conflict of Interest The authors declare that they have no competing
interests.
References
1. Liu L et al (2015) Global, regional, and national causes of child
mortality in 2000–13, with projections to inform post-2015 priori-
ties: an updated systematic analysis. Lancet 385(9966):430–440
2. Organization, W.H (2005) The treatment of diarrhoea: a manual for
physicians and other senior health workers. WHO, Geneva 2013,
WHO/CDD/SER/80.2
3. Grenov B, et al. (2017) Validation of a simple stool diary used by
caregivers to document diarrhea among young children in a low-
income country. J Pediatr Gastroenterol Nutr. doi:10.1097/MPG.
0000000000001462
4. Grandy G et al (2010) Probiotics in the treatment of acute rotavirus
diarrhoea. A randomized, double-blind, controlled trial using two
different probiotic preparations in Bolivian children. BMC Infect
Dis 10(1):253
5. Koletzko S, Osterrieder S (2009) Acute infectious diarrhea in chil-
dren. Dtsch Arztebl Int 106(33):539–547
6. Canani RB et al (2007) Probiotics for treatment of acute diarrhoea
in children: randomised clinical trial of five different preparations.
BMJ 335(7615):335–340
7. Cucchiara S et al (2002) New therapeutic approach in the manage-
ment of intestinal disease: probiotics in intestinal disease in paedi-
atric age. Dig Liver Dis 34:S44–S47
8. Lotfi A et al (2016) Comparing the effects of two feeding methods
onmetabolic bone disease in newborns with very low birth weights.
Glob J Health Sci 8(1):249–254
9. Boirivant M, Strober W (2007) The mechanism of action of
probiotics. Curr Opin Gastroenterol 23(6):679–692
10. Petrof EO (2009) Probiotics and gastrointestinal disease: clinical evi-
dence and basic science. Anti-Inflammatory & Anti-Allergy Agents in
Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-
Inflammatory and Anti-Allergy Agents) 8(3): p. 260–269
11. Sharif MR et al (2016) The effect of a yeast probiotic on acute diarrhea
in children. Probiotics and Antimicrobial Proteins 8(4):211–214
12. Allen SJ et al (2011) Probiotics for treating acute infectious diar-
rhoea. Sao Paulo Medical Journal 129(3):185–185
13. Billoo A et al (2006) Role of a probiotic (Saccharomyces boulardii)
in management and prevention of diarrhoea. World J Gastroenterol
12(28):4557
14. O’Ryan G,M et al (2014) Management of acute infectious diarrhea
for children living in resource-limited settings. Expert Rev Anti-
Infect Ther 12(5):621–632
15. Johnston BC et al (2012) Probiotics for the prevention of
Clostridium difficile–associated diarrhea: a systematic review and
meta-analysis. Ann Intern Med 157(12):878–888
16. Applegate JA et al (2013) Systematic review of probiotics for the
treatment of community-acquired acute diarrhea in children. BMC
Public Health 13(3):S16
17. Guandalini S (2011) Probiotics for prevention and treatment of
diarrhea. J Clin Gastroenterol 45:S149–S153
18. Moorthy G, Murali MR, Devaraj SN (2009) Lactobacilli facilitate
maintenance of intestinal membrane integrity during Shigella
dysenteriae 1 infection in rats. Nutrition 25(3):350–358
19. Htwe K et al (2008) Effect of Saccharomyces boulardii in the treat-
ment of acute watery diarrhea in Myanmar children: a randomized
controlled study. AmJTrop Med Hyg 78(2):214–216
20. Guarner F, Malagelada J-R (2003) Gut flora in health and disease.
Lancet 361(9356):512–519
21. Gorbach SL (2000) Probiotics and gastrointestinal health. Am J
Gastroenterol 95(1):S2–S4
22. Hempel S et al (2012) Probiotics for the prevention and treatment of
antibiotic-associated diarrhea: a systematic review and meta-analy-
sis. JAMA 307(18):1959–1969
23. Simpson H, Campbell B (2015) Review article: dietary fibre–mi-
crobiota interactions. Aliment Pharmacol Ther 42(2):158–179
24. Marrazzo, J. M., & Apicella, M. A. (2014). Neisseria gonorrhoeae
(Gonorrhea). In Mandell, Douglas, andBennett’s Principles and
Practice of Infectious Diseases. (Vol. 2). Elsevier Inc. pp. 2446-
2462.e3. doi:10.1016/B978-1-4557-4801-3.00214-9
25. Basu S et al (2007) Efficacy of Lactobacillus rhamnosus GG in
acute watery diarrhoea of Indian children: a randomised controlled
trial. J Paediatr Child Health 43(12):837–842
26. Francavilla R et al (2012) Randomised clinical trial: Lactobacillus
reuteri DSM 17938 vs. placebo in children with acute diarrhoea—a
double-blind study. Aliment Pharmacol Ther 36(4):363–369
27. Jalali HK et al (2016) Antagonistic activity of Nocardia brasiliensis
PTCC 1422 against isolated Enterobacteriaceae from urinary tract
infections. Probiotics and antimicrobial proteins 8(1):41–45
28. Ferdosian M et al (2015) Identification of immunotopes against
Mycobacterium leprae as immune targets using PhDTm-12mer
phage display peptide library. Trop J Pharm Res 14(7):1153–1159
29. Kashani HH, Moniri R (2015) Expression of recombinant pET22b-
LysK-cysteine/histidine-dependent amidohydrolase/peptidase bac-
teriophage therapeutic protein in Escherichia coli BL21 (DE3).
Osong public health and research perspectives 6(4):256–260
Probiotics & Antimicro. Prot.
30. Kashani HH, et al. (2012) Synergism effect of nisin peptide in
reducing chemical preservatives in food industry. Life Science
Journal 9(1):496–501
31. Dehghani R et al (2016a) The identification of bacterial flora in oral
cavity of snakes. Comp Clin Pathol 25(2):279–283
32. Dehghani R et al (2016b) Fungal flora in the mouth of venomous
and non-venomous snakes. Comp Clin Pathol 25(6):1207–1211
33. Kashani HH et al (2013) Expression of galectin-3 as a testis inflamma-
tory marker in vasectomised mice. Cell J 15(1):11–18
34. Nikzad H et al (2013) Expression of galectin-8 on human endome-
trium:molecular and cellular aspects. Iran J ReprodMed 11(1):65–70
35. Korviakova E (1999)Use of loading doses of bifidumbacterin forte
for treatment of patients with acute enteric infections. Zhurnal
mikrobiologii, epidemiologii, i immunobiologii (6): p. 58–61
36. Utemuradova G (2008) Etiology of acute enteric n in children with
arid zone and effect of probiotics. Zhurnal mikrobiologii,
epidemiologii, i immunobiologii (3): p. 98–100
37. Vandenplas Yet al (2007) Probiotics in infectious diarrhoea in chil-
dren: are they indicated? Eur J Pediatr 166(12):1211–1218
38. Erdoğan Ö, et al. (2012) The comparition of the efficacy of two
different probiotics in rotavirus gastroenteritis in children. J Trop
Med 2012;787240. doi:10.1155/2012/787240
39. GuarinoA et al (2014) European Society for Pediatric Gastroenterology,
Hepatology, and Nutrition/European Society for Pediatric Infectious
Diseases evidence-based guidelines for the management of acute gas-
troenteritis in children in Europe: update 2014. J Pediatr Gastroenterol
Nutr 59(1):132–152
40. Mirnejad R et al (2013) The antimicrobial effect of lactobacillus
casei culture supernatant against multiple drug resistant clinical
isolates of Shigella sonnei and Shigella flexneri in vitro. Iranian
Red Crescent medical journal 15(2):122–126
Probiotics & Antimicro. Prot.
